NASDAQ: TCRXTscan Therapeutics Inc Stock
$5.55-0.08 (-1.42%)
Updated Sep 6, 2024
TCRX Price
$5.55
Fair Value Price
N/A
Market Cap
$294.00M
52 Week Low
$2.35
52 Week High
$9.69
P/E
-5.84x
P/B
1.15x
P/S
54.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.20M
Earnings
-$104.41M
Gross Margin
100%
Operating Margin
-825.15%
Profit Margin
-855.8%
Debt to Equity
0.47
Operating Cash Flow
-$71M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TCRX Overview
TScan Therapeutics Incorporated is a preclinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for the treatment of cancer. TSC-100 and TSC-101 are intended to treat patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 are intended to treat solid tumors.The company was incorporated in 2018 and is headquartered in Waltham, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TCRX is good value based on its book value relative to its share price (1.15x), compared to the US Biotechnology industry average (6.22x)
P/B vs Industry Valuation
TCRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TCRX due diligence checks available for Premium users.
Be the first to know about important TCRX news, forecast changes, insider trades & much more!
TCRX News
Valuation
TCRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.84x
Industry
-46.85x
Market
24.57x
TCRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.15x
Industry
6.22x
TCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TCRX's financial health
Profit margin
Revenue
$536.0k
Net Income
-$31.7M
Profit Margin
-5,906.9%
TCRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$374.9M
Liabilities
$119.7M
Debt to equity
0.47
TCRX's short-term assets ($299.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRX's short-term assets ($299.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.2M
Investing
-$33.7M
Financing
$161.6M
TCRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCRX vs Biotech Stocks
Tscan Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.